aleniglipron vs MDR-001
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
aleniglipron
Developed by Structure Therapeutics
NCT06703021 · Phase 2 · completed
The study was randomized, triple-blind, and placebo-controlled, with 85 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Registered primary outcomes are safety measures; the weight-loss figures are the trial's prespecified efficacy readout, reported in the sponsor's topline press release and not yet peer reviewed. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: September 2028 · NCT07654361 (registry estimate)
Reported efficacy
Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) (Baseline and week 44); Adverse events of special interest (Baseline and week 44); Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters, including hematology, plasma chemistry, coagulation, and urinalysis (Baseline and week 44); Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters: Common ECG-related variables will be assessed, including but not limited to : heart rate and QRS duration (Baseline and week 44); Number of Participants With Clinically Significant Change From Baseline in Vital Signs, including systolic and diastolic Blood Pressure, Heart Rate, Respiratory Rate, and temperature (Baseline and week 44): Placebo-adjusted mean weight loss 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks (both p<0.0001) (not_applicable)
Result source: NCT06703021
MDR-001
Developed by MindRank AI
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07274137 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | aleniglipron | MDR-001 |
|---|---|---|
| Body weight, % change | —Trial running · NCT07654361 | —Trial running · NCT07274137 |
| Weight loss of 5% or more | —Trial running · NCT07654361 | —Trial running · NCT07274137 |
| Weight loss of 10% or more | —Trial running · NCT07654361 | —Trial running · NCT07274137 |
| Waist circumference, change (cm) | —Trial running · NCT07654361 | —Trial running · NCT07274137 |
Body weight, % change
- aleniglipron
- —Trial running · NCT07654361
- MDR-001
- —Trial running · NCT07274137
Weight loss of 5% or more
- aleniglipron
- —Trial running · NCT07654361
- MDR-001
- —Trial running · NCT07274137
Weight loss of 10% or more
- aleniglipron
- —Trial running · NCT07654361
- MDR-001
- —Trial running · NCT07274137
Waist circumference, change (cm)
- aleniglipron
- —Trial running · NCT07654361
- MDR-001
- —Trial running · NCT07274137
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
MDR-001: no structured comparison results are available for Obesity.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aleniglipron's landscape · MDR-001's landscape